JP2004524837A - 悪性細胞についての、診断的メチル化ＣｐＧリッチ配列の検出 - Google Patents
悪性細胞についての、診断的メチル化ＣｐＧリッチ配列の検出 Download PDFInfo
- Publication number
- JP2004524837A JP2004524837A JP2002560518A JP2002560518A JP2004524837A JP 2004524837 A JP2004524837 A JP 2004524837A JP 2002560518 A JP2002560518 A JP 2002560518A JP 2002560518 A JP2002560518 A JP 2002560518A JP 2004524837 A JP2004524837 A JP 2004524837A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- oligonucleotide
- dna
- target sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003211 malignant effect Effects 0.000 title claims abstract description 33
- 238000001514 detection method Methods 0.000 title description 24
- 108020004414 DNA Proteins 0.000 claims abstract description 293
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 207
- 239000012634 fragment Substances 0.000 claims abstract description 195
- 230000011987 methylation Effects 0.000 claims abstract description 120
- 238000007069 methylation reaction Methods 0.000 claims abstract description 120
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 104
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 83
- 239000002157 polynucleotide Substances 0.000 claims abstract description 83
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 74
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 72
- 201000011510 cancer Diseases 0.000 claims abstract description 57
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000002773 nucleotide Substances 0.000 claims description 101
- 125000003729 nucleotide group Chemical group 0.000 claims description 101
- 239000000499 gel Substances 0.000 claims description 92
- 108091029523 CpG island Proteins 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 71
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 68
- 230000000295 complement effect Effects 0.000 claims description 57
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 42
- 238000003752 polymerase chain reaction Methods 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 229940104302 cytosine Drugs 0.000 claims description 26
- 238000009396 hybridization Methods 0.000 claims description 23
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 22
- 206010018338 Glioma Diseases 0.000 claims description 21
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 21
- 229940035893 uracil Drugs 0.000 claims description 21
- 208000020816 lung neoplasm Diseases 0.000 claims description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims description 19
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 18
- 208000032612 Glial tumor Diseases 0.000 claims description 17
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 16
- 208000029742 colonic neoplasm Diseases 0.000 claims description 16
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 16
- 201000005202 lung cancer Diseases 0.000 claims description 16
- 201000003120 testicular cancer Diseases 0.000 claims description 15
- 230000002441 reversible effect Effects 0.000 claims description 13
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 12
- 206010057644 Testis cancer Diseases 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 210000000481 breast Anatomy 0.000 claims description 10
- 238000001962 electrophoresis Methods 0.000 claims description 10
- 201000010536 head and neck cancer Diseases 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 6
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 5
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 abstract description 21
- 230000007017 scission Effects 0.000 abstract description 21
- 238000003745 diagnosis Methods 0.000 abstract description 13
- 108091029430 CpG site Proteins 0.000 abstract description 12
- 238000001502 gel electrophoresis Methods 0.000 abstract description 4
- 238000004393 prognosis Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 116
- 239000000523 sample Substances 0.000 description 53
- 230000029087 digestion Effects 0.000 description 28
- 239000000872 buffer Substances 0.000 description 23
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical group [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 238000002105 Southern blotting Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000000376 autoradiography Methods 0.000 description 13
- 239000011521 glass Substances 0.000 description 13
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 229920000936 Agarose Polymers 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 102100031780 Endonuclease Human genes 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 229920006362 Teflon® Polymers 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 208000037841 lung tumor Diseases 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010042546 GCGGCCGC-specific type II deoxyribonucleases Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000000163 radioactive labelling Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940124466 diagnostic for cancer Drugs 0.000 description 3
- 230000008995 epigenetic change Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000030173 low grade glioma Diseases 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000025189 neoplasm of testis Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006298 saran Polymers 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000007855 methylation-specific PCR Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108091030081 DNA N(4)-methylcytosine Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/775,398 US6893820B1 (en) | 2001-01-31 | 2001-01-31 | Detection of methylated CpG rich sequences diagnostic for malignant cells |
| PCT/US2002/003077 WO2002060318A2 (en) | 2001-01-31 | 2002-01-31 | Detection of methylated cpg rich sequences diagnostic for malignant cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004524837A true JP2004524837A (ja) | 2004-08-19 |
| JP2004524837A5 JP2004524837A5 (enExample) | 2005-08-04 |
Family
ID=25104283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002560518A Pending JP2004524837A (ja) | 2001-01-31 | 2002-01-31 | 悪性細胞についての、診断的メチル化ＣｐＧリッチ配列の検出 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6893820B1 (enExample) |
| EP (1) | EP1373567A4 (enExample) |
| JP (1) | JP2004524837A (enExample) |
| CA (1) | CA2435770A1 (enExample) |
| WO (1) | WO2002060318A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008529524A (ja) * | 2005-02-15 | 2008-08-07 | サムスン エレクトロニクス カンパニー リミテッド | 多座マーカを利用した２型糖尿病の診断方法、２型糖尿病に関連したマーカを含むポリヌクレオチド、それを含むマイクロアレイ及び２型糖尿病診断用キット |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6893820B1 (en) * | 2001-01-31 | 2005-05-17 | The Ohio State University Research Foundation | Detection of methylated CpG rich sequences diagnostic for malignant cells |
| US20050064412A1 (en) * | 2001-08-23 | 2005-03-24 | Toshikazu Ushijima | Method of evaluating degree of canceration of mammal-origin specimen |
| WO2004018668A1 (ja) * | 2002-08-23 | 2004-03-04 | Sumitomo Chemical Company, Limited | ヒト由来の検体の癌化度を評価する方法 |
| US8206913B1 (en) | 2003-03-07 | 2012-06-26 | Rubicon Genomics, Inc. | Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process |
| US20050118613A1 (en) * | 2003-08-01 | 2005-06-02 | Oncomethylome Sciences S.A. | Methods and kits for predicting the likelihood of successful treatment of cancer |
| EP2395111B1 (en) * | 2003-10-08 | 2015-05-13 | Trustees of Boston University | Methods for prenatal diagnosis of chromosomal abnormalities |
| JP2007524407A (ja) | 2003-12-29 | 2007-08-30 | ニューゲン テクノロジーズ， インコーポレイテッド | 核酸のメチル化状態を分析するための方法、ならびに核酸の断片化、標識化および固定化のための方法 |
| CA2902980A1 (en) | 2004-03-08 | 2005-09-29 | Rubicon Genomics, Inc. | Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation |
| WO2007018601A1 (en) | 2005-08-02 | 2007-02-15 | Rubicon Genomics, Inc. | Compositions and methods for processing and amplification of dna, including using multiple enzymes in a single reaction |
| EP1924705A1 (en) | 2005-08-02 | 2008-05-28 | Rubicon Genomics, Inc. | Isolation of cpg islands by thermal segregation and enzymatic selection-amplification method |
| US7465544B2 (en) * | 2006-01-11 | 2008-12-16 | Wisconsin Alumni Research Foundation | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use |
| US20080003609A1 (en) * | 2006-05-10 | 2008-01-03 | The Cleveland Clinic Foundation | Method of detecting bladder urothelial carcinoma |
| WO2008153541A1 (en) * | 2006-09-26 | 2008-12-18 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| TWI335354B (en) * | 2006-09-27 | 2011-01-01 | Univ Hong Kong Chinese | Methods for the detection of the degree of the methylation of a target dna and kits |
| US20080102452A1 (en) * | 2006-10-31 | 2008-05-01 | Roberts Douglas N | Control nucleic acid constructs for use in analysis of methylation status |
| JP5151167B2 (ja) * | 2007-01-31 | 2013-02-27 | 住友化学株式会社 | Ｄｎａメチル化測定方法 |
| EP2126129A4 (en) * | 2007-03-02 | 2010-12-22 | Univ Ohio State Res Found | CELL TOD ASSOCIATED PROTEIN KINASE (DAPK1) AND ITS USE IN THE TREATMENT OF CHRONIC LYMPHOCYTE LYMPHIA |
| EP3124491B1 (en) | 2009-06-05 | 2019-10-30 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| SG10201510189WA (en) | 2011-10-19 | 2016-01-28 | Nugen Technologies Inc | Compositions And Methods For Directional Nucleic Acid Amplification And Sequencing |
| CN104093890B (zh) | 2012-01-26 | 2016-04-20 | 纽亘技术公司 | 用于靶向核酸序列富集和高效文库产生的组合物和方法 |
| EP3563834A1 (en) | 2012-02-07 | 2019-11-06 | Infectious Disease Research Institute | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same |
| EA034351B1 (ru) | 2012-05-16 | 2020-01-30 | Иммьюн Дизайн Корп. | Трехкомпонентная вакцина против впг-2 и способы ее применения |
| US9957549B2 (en) | 2012-06-18 | 2018-05-01 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
| US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
| EP2971130A4 (en) | 2013-03-15 | 2016-10-05 | Nugen Technologies Inc | SEQUENTIAL SEQUENCING |
| CN105209047B (zh) | 2013-04-18 | 2020-08-18 | 免疫设计股份有限公司 | 用于癌症治疗的gla单一疗法 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| CN105849264B (zh) | 2013-11-13 | 2019-09-27 | 纽亘技术公司 | 用于鉴别重复测序读数的组合物和方法 |
| IL310015B1 (en) | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| US9745614B2 (en) | 2014-02-28 | 2017-08-29 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
| CA2957633A1 (en) | 2014-08-06 | 2016-02-11 | Nugen Technologies, Inc. | Digital measurements from targeted sequencing |
| WO2016061624A1 (en) * | 2014-10-20 | 2016-04-28 | Commonwealth Scientific And Industrial Research Organisation | Genome methylation analysis |
| AU2017273650B2 (en) | 2016-06-01 | 2022-08-18 | Access To Advanced Health Institute | Nanoalum particles containing a sizing agent |
| US12492430B2 (en) | 2017-04-11 | 2025-12-09 | Tecan Genomics, Inc. | Library quantitation and qualification |
| KR102755593B1 (ko) | 2017-09-08 | 2025-01-20 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사포닌을 포함하는 리포솜 제형 및 사용 방법 |
| US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
| MX2021014363A (es) | 2019-05-25 | 2022-02-21 | Infectious Disease Res Inst | Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante. |
| US12059674B2 (en) | 2020-02-03 | 2024-08-13 | Tecan Genomics, Inc. | Reagent storage system |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017704A (en) * | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US6331393B1 (en) * | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US6893820B1 (en) * | 2001-01-31 | 2005-05-17 | The Ohio State University Research Foundation | Detection of methylated CpG rich sequences diagnostic for malignant cells |
-
2001
- 2001-01-31 US US09/775,398 patent/US6893820B1/en not_active Expired - Lifetime
-
2002
- 2002-01-31 EP EP02709295A patent/EP1373567A4/en not_active Withdrawn
- 2002-01-31 JP JP2002560518A patent/JP2004524837A/ja active Pending
- 2002-01-31 CA CA 2435770 patent/CA2435770A1/en not_active Abandoned
- 2002-01-31 WO PCT/US2002/003077 patent/WO2002060318A2/en not_active Ceased
-
2004
- 2004-05-10 US US10/842,072 patent/US20050158731A1/en not_active Abandoned
-
2007
- 2007-05-01 US US11/742,663 patent/US20070259364A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008529524A (ja) * | 2005-02-15 | 2008-08-07 | サムスン エレクトロニクス カンパニー リミテッド | 多座マーカを利用した２型糖尿病の診断方法、２型糖尿病に関連したマーカを含むポリヌクレオチド、それを含むマイクロアレイ及び２型糖尿病診断用キット |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2435770A1 (en) | 2002-08-08 |
| US6893820B1 (en) | 2005-05-17 |
| EP1373567A2 (en) | 2004-01-02 |
| US20050158731A1 (en) | 2005-07-21 |
| WO2002060318A2 (en) | 2002-08-08 |
| US20070259364A1 (en) | 2007-11-08 |
| WO2002060318A3 (en) | 2003-10-09 |
| EP1373567A4 (en) | 2005-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6893820B1 (en) | Detection of methylated CpG rich sequences diagnostic for malignant cells | |
| KR101569498B1 (ko) | 위용종 및 위암 특이적 메틸화 마커 유전자를 이용한 위용종 및 위암의 검출방법 | |
| US5912147A (en) | Rapid means of quantitating genomic instability | |
| EP3828291A1 (en) | Methylation modification-based tumor marker stamp-ep1 | |
| EP2046985A1 (en) | Method for the detection of egfr mutations in blood samples | |
| EP3828273A1 (en) | Methylation modification-based tumor marker stamp-ep2 | |
| EP3029148B1 (en) | Method for determining nucleic acid composition of nucleic acid mixture | |
| EP2304057A2 (en) | Method for the detection of ovarian cancer | |
| JP2009514555A (ja) | 癌評価の遺伝子関連ＣｐＧアイランドのメチル化アッセイのための材料と方法 | |
| CN113122637B (zh) | 检测dna甲基化的试剂及用途 | |
| CA2269664C (en) | Diagnostic assay for breast cancer susceptibility | |
| JP7383051B2 (ja) | メチル化修飾に基づく腫瘍マーカーｓｔａｍｐ－ｅｐ８及びその応用 | |
| JPWO2020116573A1 (ja) | 子宮体癌の予後の判定方法 | |
| CN110791567B (zh) | 一种单个位点dna甲基化检测试剂盒 | |
| KR101145406B1 (ko) | 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법 | |
| EP2922973A1 (en) | A method of detecting methylation | |
| AU2002243787B2 (en) | Detection of methylated CpG rich sequences diagnostic for malignant cells | |
| US7094538B2 (en) | Diagnostic assay for cancer susceptibility | |
| JP4315812B2 (ja) | 癌腫の分子診断および予後 | |
| Lin et al. | Promoter hypermethylation of p16 gene and DAPK gene in sera from hepatocellular carcinoma (HCC) patients | |
| JP4359497B2 (ja) | 核酸増幅用プライマー、核酸増幅用プライマーセット及びこれを用いた癌の検査方法 | |
| JP4682275B2 (ja) | 哺乳動物の神経芽細胞腫の予後を判定する方法 | |
| CN120648795A (zh) | 用于检测卵巢病变的组合物及其用途 | |
| AU2002243787A1 (en) | Detection of methylated CpG rich sequences diagnostic for malignant cells | |
| KR101136505B1 (ko) | 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080414 |